<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882827</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-014-MDYF</org_study_id>
    <nct_id>NCT03882827</nct_id>
  </id_info>
  <brief_title>Natural History of Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Prospective, Interventional, Baseline Study In Young Male Subjects Aged From 5 to 9 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Baseline Study on Duchenne Muscular Dystrophy (DMD) in view to collect data on the natural&#xD;
      disease course in a cohort in young male subjects aged from 5 to 9 Years over a period of 6&#xD;
      to 36 months using disease appropriate evaluations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration from FPFV: Q1 2019 to LPLV: Q3 2023&#xD;
&#xD;
      Primary Ojectives:&#xD;
&#xD;
        -  To assess the natural disease course using standardized and disease appropriate&#xD;
           evaluations over a period of 6 to 36 months in a cohort of young male subjects aged from&#xD;
           5 to 9 years at inclusion and diagnosed for Duchenne Muscular Dystrophy (DMD).&#xD;
&#xD;
        -  To record a baseline period prior to the setup of an AAV gene therapy dose escalation&#xD;
           phase I/II First in Man clinical study.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To identify clinical, imaging and/or laboratory parameters that could be predictive&#xD;
           indicators of the disease course in DMD, within the selected range of age.&#xD;
&#xD;
        -  To identify the best outcome measure(s) for further clinical trial assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NSAA scale</measure>
    <time_frame>Screening 36 months</time_frame>
    <description>NSAA scale (age appropriate modified North Star Ambulatory Assessment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10 Meter Walk/ Run test (10MW/RT)</measure>
    <time_frame>Screening 36 months</time_frame>
    <description>Time function Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Minutes Walk Test (6 MWT)</measure>
    <time_frame>Screening 36 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myoset : Myo-grip, -pinch</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTIMYO</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Motor Function Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Imaging Nuclear Magnetic Resonance Imaging (NMRI)</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Muscle Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Test (PFT)</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Respiratory Function Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG - Echocardiography</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Cardiac Function Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTIVLIM</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Patient Reported Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Inclusion 36 months</time_frame>
    <description>Questionnaire of Life</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male 5 to 9 years old inclusive Body-Weight &lt; or = 75th percentile of BMI Body-Mass Index&#xD;
        scale&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. 5 to 9 years old inclusive&#xD;
&#xD;
          3. Body-Weight &lt; or = 75th percentile of BMI body-mass index scale (according to&#xD;
             validated scale in force in the country site)&#xD;
&#xD;
          4. Diagnosis of DMD based upon Gene testing positive with detailed genotyping&#xD;
&#xD;
          5. Able to achieve:&#xD;
&#xD;
               -  NSAA (North Star Ambulatory Assessment) scale &gt; or =18 (with a maximum of 2&#xD;
                  points difference between inclusion and screening visits) and/or:&#xD;
&#xD;
               -  Gowers test &lt; or =7 sec&#xD;
&#xD;
               -  6 Minute Walk Test (6MWT) &gt; or = 350 meters at screening visit (M1) and at&#xD;
                  inclusion visit (M0) with the distance being 20% of each other&#xD;
&#xD;
          6. Ongoing corticosteroid therapy or initiation of corticosteroid therapy according to&#xD;
             standard of care in the previous 3 months&#xD;
&#xD;
          7. Signed informed consent by at least one parent(s) or both parents or legal guardian&#xD;
             representative(s), when applicable and according to the country regulation&#xD;
&#xD;
          8. Affiliated Beneficiary of the National Health Care scheme&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          9. Cardiomyopathy based on physical cardiological examination and echocardiography with&#xD;
             Left Ventricular Ejection Fraction (LVEF) below 55%&#xD;
&#xD;
         10. Respiratory Assistance: need for either a diurnal and/or a nocturnal ventilation&#xD;
&#xD;
         11. Any co-morbidity (ies) and or previous or planned surgical event(s) which may&#xD;
             interfere with DMD natural evolution and or evaluation of outcomes designed to assess&#xD;
             DMD Natural History&#xD;
&#xD;
         12. Muscle testing: inability to cooperate with&#xD;
&#xD;
         13. Nuclear Magnetic Resonance Imaging (NMRI): metal implants in regions of interest for&#xD;
             the study&#xD;
&#xD;
         14. Unwilling and/or unable to comply with all the study protocol requirements and or&#xD;
             procedures&#xD;
&#xD;
         15. Previous inclusion to another clinical trial with an Investigational Medicinal Product&#xD;
             (IMP), within the 3 months (or IMP washout period) prior to the screening visit of the&#xD;
             study&#xD;
&#xD;
         16. Concomitant participation to any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco MUNTONI, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOSH LONDON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco MUNTONI, Pr</last_name>
    <phone>+44 02079052602</phone>
    <email>c.griffith@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital &amp; University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Genetic Medicine</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

